首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1794527

全球核能藥局市場

Nuclear Pharmacy

出版日期: 2025年08月20日 | 出版商:

Global Industry Analysts, Inc. | 英文 275 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2030年，全球核能藥局市場規模將達86億美元

全球核能藥局市場規模預計在2024年為61億美元，到2030年將達到86億美元，2024年至2030年的複合年成長率為5.8%。設施類型是本報告分析的細分市場之一，預計其複合年成長率為4.5%，到分析期結束時規模將達到48億美元。商業類型細分市場在分析期間內的複合年成長率預計為7.7%。

美國市場規模估計為 17 億美元，中國市場預期複合年成長率為 9.0%

美國核能藥市場規模預計2024年達到17億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到17億美元，在2024-2030年的分析期間內，複合年成長率為9.0%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為3.0%和5.7%。在歐洲，預計德國市場的複合年成長率為3.8%。

全球核能藥局市場－主要趨勢與促進因素摘要

為什麼核能藥學在現代醫療保健中越來越受到關注？

核能醫學藥局已成為診斷和治療醫學的重要組成部分，因為它們在核子醫學攝影影像和標靶治療所用放射性藥物的製備中發揮關鍵作用。隨著腫瘤科、心臟科和神經科對精準診斷的需求日益成長，核醫藥局已成為向影像中心和醫院提供時間敏感、病患特異性放射性藥物的關鍵。這些化合物能夠在分子層面上可視化生物過程，從而能夠更早發現疾病並更精確地監測治療反應。

除了診斷影像外，核能藥房也在拓展其在治療診斷學的作用，即將治療和診斷功能整合到單一放射性藥物中。這種整合支持更個人化的患者照護方法，其中特定同位素可用於識別和治療腫瘤。隨著醫療保健向微創和標靶治療轉變，核能藥局預計將在臨床工作流程中發揮越來越重要的作用。

放射性藥物和同位素生產的進步如何推動成長？

新型放射性藥物的開發正在拓展核能藥學的應用範圍，使其超越Technetium-99m和氟-18等傳統示蹤劑。新的藥物正在被設計用於更特異性的疾病靶點，包括用鎦-177和鎵-68等同位素標記的胜肽和抗體。這些化合物正用於治療前列腺癌、神經內分泌腫瘤和其他疑難雜症，為專業化核能藥學運作創造了機會。

同位素生產也正在經歷變革時期。基於迴旋加速器和發生器的生產技術正在提高短壽命同位素的可靠性和本地可用性，減少對老化核子反應爐的依賴。自動化合成模組和品管系統正在改進放射性藥物的製備，標準化劑量，並降低藥劑師的暴露風險。這些創新支持以更快、更安全、更具可擴展性的方式向醫療保健專業人員提供放射性藥物。

市場擴張的結構和監管促進因素是什麼？

核能藥房在處理放射性物質方面受到嚴格的監管。遵守國家和國際標準需要專門的基礎設施、人員培訓和許可，這限制了能夠進行大規模運作的設施數量。然而，集中式、連網的放射性藥物藥房的成長正在幫助醫療保健系統改善物流，減少廢棄物，並確保準時交付短半衰期放射性藥物。

門診診斷中心和綜合護理網路的興起進一步影響了核能藥房的擴張。許多醫療系統正在投資內部或附屬的放射性藥物生產能力，以減少對外部供應商的依賴。公共和私人對腫瘤學的資助，加上監管機構對新型放射性藥物的快速反應，正在加強供應鏈並加速市場發展。製藥公司、同位素製造商和醫療保健提供者之間的夥伴關係也在不斷湧現，以滿足日益成長的臨床需求。

核能藥局市場的成長受到多種因素的推動。

核子醫學影像和治療診斷學在腫瘤學、循環系統和神經病學中的應用日益廣泛，這推動了對及時、高品質放射性藥物的需求。新型同位素和靶向放射性示蹤劑的開發正在擴大臨床應用範圍。自動化合成和同位素生產技術的進步正在提高操作效率和安全性。集中式放射性藥物製造模式的擴展使得人們能夠更廣泛地獲得時間關鍵型診斷劑。對新型放射治療的監管支持和對個人化醫療的不斷成長的投資正在加強核能藥房與標準治療通訊協定的整合。這些綜合因素正在為全球核能藥局市場創造強勁的成長軌跡。

部分

類型（設施類型、商業類型）；用途（診斷、治療）

受訪公司範例

Advanced Accelerator Applications（AAA）
Bayer AG（Radiopharma division）
Bracco Imaging SpA
Cardinal Health, Inc.（Nuclear Pharmacy）
Curium Pharma
Eczacibasi-Monrol Nuclear Products
Eckert & Ziegler（Radiopharma division）
GE HealthCare（Nuclear Pharmacy Services）
IBA Molecular Imaging
Jubilant Radiopharma（Jubilant DraxImage）
Lantheus Medical Imaging, Inc.
Mallinckrodt plc.（Nuclear Imaging）
NTP Radioisotopes SOC Ltd.
Nihon Medi-Physics Co., Ltd.
Nordion Inc.（Sotera Health）
Novartis（Advanced Accelerator Applications）
PharmaLogic Holdings Corp.
Siemens Healthineers
Shine Technologies（SHINE Medical）
Telix Pharmaceuticals Limited

人工智慧整合

利用檢驗的專家內容和 AI 工具轉變您的市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

The global market for Nuclear Pharmacy estimated at US$6.1 Billion in the year 2024, is expected to reach US$8.6 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Institutional Type, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Commercial Type segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 9.0% CAGR

The Nuclear Pharmacy market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Nuclear Pharmacy Market - Key Trends & Drivers Summarized

Why Is Nuclear Pharmacy Gaining Prominence in Modern Healthcare?

Nuclear pharmacy is emerging as a critical component of diagnostic and therapeutic medicine due to its role in preparing radiopharmaceuticals used in nuclear imaging and targeted treatments. As demand rises for precision diagnostics in oncology, cardiology, and neurology, nuclear pharmacies are becoming essential in supplying time-sensitive, patient-specific radiotracers to imaging centers and hospitals. These compounds help visualize biological processes at the molecular level, enabling early detection of disease and more accurate monitoring of treatment response.

In addition to diagnostic imaging, nuclear pharmacy plays a growing role in theranostics-where therapeutic and diagnostic capabilities are combined in a single radiopharmaceutical. This integration supports a more personalized approach to patient care, where specific isotopes can be used to both identify and treat tumors. As healthcare shifts toward minimally invasive and targeted interventions, nuclear pharmacy is expected to play an increasingly central role in clinical workflows.

How Are Advancements in Radiopharmaceuticals and Isotope Production Driving Growth?

The development of new radiopharmaceuticals is expanding the scope of nuclear pharmacy beyond conventional tracers such as technetium-99m and fluorine-18. Novel agents are being designed for more specific disease targeting, including peptides and antibodies labeled with isotopes like lutetium-177 and gallium-68. These compounds are being used in the management of prostate cancer, neuroendocrine tumors, and other hard-to-treat conditions, creating opportunities for specialized nuclear pharmacy operations.

Isotope production is also undergoing transformation. Cyclotron and generator-based production techniques are improving reliability and local availability of short-lived isotopes, reducing dependency on aging nuclear reactors. Automated synthesis modules and quality control systems are improving radiopharmaceutical preparation, standardizing dosage, and reducing exposure risks to pharmacy personnel. These innovations are supporting faster, safer, and more scalable delivery of radiotracers to healthcare providers.

What Structural and Regulatory Factors Influence Market Expansion?

Nuclear pharmacy operates under strict regulatory controls given the handling of radioactive materials. Compliance with national and international standards requires specialized infrastructure, staff training, and licensing, which limits the number of facilities that can operate at scale. However, growth in centralized and networked radiopharmacies is helping healthcare systems improve logistics, reduce waste, and ensure on-time delivery of radiopharmaceuticals with short half-lives.

The rise of outpatient diagnostic centers and integrated care networks is further influencing nuclear pharmacy expansion. Many health systems are investing in in-house or partnered radiopharmacy capabilities to reduce reliance on external suppliers. Public and private funding in cancer care, coupled with regulatory fast-tracking of novel radiotherapeutics, is strengthening supply chains and accelerating market development. Partnerships between pharmaceutical companies, isotope producers, and healthcare providers are also emerging to meet rising clinical demand.

Growth in the nuclear pharmacy market is driven by several factors.

Increased use of nuclear imaging and theranostics in oncology, cardiology, and neurology is boosting demand for timely, high-quality radiopharmaceuticals. Development of novel isotopes and targeted radiotracers is expanding the range of clinical applications. Advances in automated synthesis and isotope production technologies are improving operational efficiency and safety. Expansion of centralized radiopharmacy models is enabling wider access to time-sensitive diagnostic agents. Regulatory support for new radiotherapeutics and growing investment in personalized medicine are reinforcing the integration of nuclear pharmacy into standard care protocols. These factors are collectively shaping a strong growth trajectory for the nuclear pharmacy market globally.

SCOPE OF STUDY:

The report analyzes the Nuclear Pharmacy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Institutional Type, Commercial Type); Purpose (Diagnostic, Therapeutic)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

Advanced Accelerator Applications (AAA)
Bayer AG (Radiopharma division)
Bracco Imaging S.p.A.
Cardinal Health, Inc. (Nuclear Pharmacy)
Curium Pharma
Eczacibasi-Monrol Nuclear Products
Eckert & Ziegler (Radiopharma division)
GE HealthCare (Nuclear Pharmacy Services)
IBA Molecular Imaging
Jubilant Radiopharma (Jubilant DraxImage)
Lantheus Medical Imaging, Inc.
Mallinckrodt plc. (Nuclear Imaging)
NTP Radioisotopes SOC Ltd.
Nihon Medi-Physics Co., Ltd.
Nordion Inc. (Sotera Health)
Novartis (Advanced Accelerator Applications)
PharmaLogic Holdings Corp.
Siemens Healthineers
Shine Technologies (SHINE Medical)
Telix Pharmaceuticals Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Nuclear Pharmacy - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Demand for Targeted Diagnostic Imaging Drives Growth in Nuclear Pharmacy Services
- Expansion of PET and SPECT Imaging in Oncology, Cardiology, and Neurology Boosts Radiopharmaceutical Usage
- Increased Availability of Short-Lived Isotopes Spurs Growth in Centralized and In-Hospital Nuclear Pharmacies
- Advancements in Cyclotron and Generator Technologies Enhance On-Demand Radiotracer Production
- Regulatory Approvals for New Radiolabeled Drugs Strengthen Market for Precision Diagnostic Tools
- Shift Toward Personalized Medicine Throws the Spotlight on Radiotheranostics and Companion Diagnostics
- Growing Use of Radiopharmaceuticals in Therapeutic Applications Expands Scope of Nuclear Pharmacy Operations
- Integration of Automation and Robotics in Radiopharmacies Improves Accuracy, Safety, and Throughput
- Expansion of Academic and Clinical Research Programs Fuels Demand for Custom Radiopharmaceutical Compounding
- Rising Incidence of Chronic and Age-Related Diseases Accelerates Investment in Nuclear Imaging Infrastructure
- Improvements in Cold-Chain Logistics and Dose Scheduling Support Wider Distribution of Time-Sensitive Isotopes
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Nuclear Pharmacy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Institutional Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Commercial Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: World 16-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: USA 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 20: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: USA 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
CANADA
- TABLE 23: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: Canada Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: Canada 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 26: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: Canada 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
JAPAN
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 29: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Japan Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: Japan 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 32: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: Japan 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
CHINA
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 35: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: China Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: China 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 38: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: China Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: China 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
EUROPE
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 41: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 42: Europe Historic Review for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: Europe 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 44: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
FRANCE
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 50: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: France Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: France 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 53: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: France Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: France 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
GERMANY
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 56: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Germany Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: Germany 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 59: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: Germany 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
ITALY
- TABLE 62: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Italy Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: Italy 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 65: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: Italy 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
UNITED KINGDOM
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 68: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: UK Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: UK 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 71: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: UK 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
SPAIN
- TABLE 74: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Spain Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: Spain 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 77: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Spain Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: Spain 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
RUSSIA
- TABLE 80: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Russia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: Russia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 83: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Russia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: Russia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
REST OF EUROPE
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
ASIA-PACIFIC
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 93: Asia-Pacific Historic Review for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
AUSTRALIA
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 101: Australia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Australia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: Australia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 104: Australia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Australia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 106: Australia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
INDIA
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 107: India Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: India Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 109: India 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 110: India Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: India Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 112: India 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
SOUTH KOREA
- TABLE 113: South Korea Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: South Korea Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 115: South Korea 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 116: South Korea Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: South Korea Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 118: South Korea 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Rest of Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
LATIN AMERICA
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 125: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 126: Latin America Historic Review for Nuclear Pharmacy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 127: Latin America 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 128: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Latin America Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 130: Latin America 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 131: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Latin America Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 133: Latin America 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
ARGENTINA
- TABLE 134: Argentina Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Argentina Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 136: Argentina 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 137: Argentina Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Argentina Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 139: Argentina 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
BRAZIL
- TABLE 140: Brazil Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Brazil Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 142: Brazil 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 143: Brazil Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Brazil Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 145: Brazil 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
MEXICO
- TABLE 146: Mexico Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Mexico Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 148: Mexico 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 149: Mexico Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Mexico Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 151: Mexico 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Rest of Latin America Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 154: Rest of Latin America 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Rest of Latin America Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 157: Rest of Latin America 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
MIDDLE EAST
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 158: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 159: Middle East Historic Review for Nuclear Pharmacy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 160: Middle East 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 161: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Middle East Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 163: Middle East 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 164: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Middle East Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 166: Middle East 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
IRAN
- TABLE 167: Iran Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Iran Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 169: Iran 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 170: Iran Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Iran Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 172: Iran 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
ISRAEL
- TABLE 173: Israel Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: Israel Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 175: Israel 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 176: Israel Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Israel Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 178: Israel 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
SAUDI ARABIA
- TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Saudi Arabia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 181: Saudi Arabia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Saudi Arabia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 184: Saudi Arabia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 185: UAE Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: UAE Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 187: UAE 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 188: UAE Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: UAE Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 190: UAE 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Rest of Middle East Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 193: Rest of Middle East 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Middle East Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 196: Rest of Middle East 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
AFRICA
- Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 197: Africa Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Africa Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 199: Africa 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
- TABLE 200: Africa Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: Africa Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 202: Africa 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030